Skip to main content
. Author manuscript; available in PMC: 2014 May 6.
Published in final edited form as: Leukemia. 2013 Jun 14;27(9):1832–1840. doi: 10.1038/leu.2013.180

Figure 4. Effect of TLR2 activation in in vitro cultured primary normal bone marrow CD34+ cells.

Figure 4

(a) Flow cytometry analysis of normal CD34+ cells after being treated with MALP2 or PAM3CSK4 for 48 hours. Compared to control, treatment resulted in a decreased percentage of early erythroid progenitor cells marked with CD71+ and HLADR-. (b) Summary of flow cytometry analysis of CD71+ and HLADR- cells in primary BM CD34+ cells of four different donors. (c) Methocult medium supported colony formation assays revealed the decreased formation of erythroid colonies (CFU-E) from primary BM CD34+ cells treated by TLR2 agonist MALP2, PAM3CSK4 or IL-8.